Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation. It contains 32 cysteine residues and the complete folded molecule includes 4 ...
Pembrolizumab is indicated for the following conditions:
For all approved adult indications, pembrolizumab may be used for an additional 6 weeks at 400mg weekly.
Call for Information (Investigational Site 0083), Los Angeles, California, United States
Call for Information (Investigational Site 0021), Orange, California, United States
Call for Information (Investigational Site 0085), Chicago, Illinois, United States
Cancer Therapy & Research Center at UTHSCSA, San Antonio, Texas, United States
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
University of Chicago, Chicago, Illinois, United States
NYU Perlmutter Cancer Center, New York, New York, United States
Memorial Sloan Kettering, New York, New York, United States
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Indiana University Hospital, Indianapolis, Indiana, United States
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
Jewish General Hospital, Montreal, Quebec, Canada
Hopital Notre-Dame, Montreal, Quebec, Canada
Cedars-Sinai Medical Center, Los Angeles, California, United States
John Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
University of Chicago, Chicago, Illinois, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.